IJDDP/
Articles/
2504000146
  • Open Access
  • Article
Metformin Inhibits Autophagy, Mitophagy and Antagonizes Doxorubicin-Induced Cardiomyocyte Death
  • Jennifer Van 1,   
  • Younghee Hahn 1,   
  • Brett Silverstein 1,   
  • Cairong Li 2,   
  • Fei Cai 2,   
  • Jia Wei 3,   
  • Lokesh Katiki 1,   
  • Puja Mehta 1,   
  • Katherine Livatova 1,   
  • Jaclyn DelPozzo 1,   
  • Tamayo Kobayashi 1,   
  • Yuan Huang 1,   
  • Satoru Kobayashi 1,   
  • Qiangrong Liang 1, *

Received: 28 Nov 2022 | Accepted: 12 Jan 2023 | Published: 17 Feb 2023

Abstract

The antidiabetic drug metformin has been shown to reduce cardiac injury under various pathological conditions, including anticancer drug doxorubicin (DOX)-induced cardiotoxicity, which makes metformin a prime candidate for repurposing. However, the mechanisms that mediate the cardioprotective effects of metformin remain highly controversial. In this study, we tested a prevailing hypothesis that metformin activates autophagy/mitophagy to reduce DOX cardiotoxicity. FVB/N mice and H9C2 cardiac myoblasts were treated with metformin, respectively. Autophagy/mitophagy was determined by Western blot analysis of microtubule-associated protein light chain 3, form-II (LC3-II), a well-established marker of autophagic vesicles. Although metformin had minimal effects on basal LC3-II levels, it significantly inhibited the accumulation of LC3-II levels by the lysosomal protease inhibitors pepstatin A and E64d in both total cell lysates and mitochondrial fractions. Also, dual fluorescent autophagy/mitophagy reporters demonstrated that metformin slowed the degradation rate of autophagic cargos or mitochondrial fragments in the lysosomes. These surprising results suggest that metformin inhibits rather than stimulates autophagy/mitophagy, sharply contrasting the popular belief. In addition, metformin diminished DOX-induced autophagy/mitophagy as well as cardiomyocyte death. Together, these results suggest that the cardioprotective effects of metformin against DOX cardiotoxicity may be mediated by its ability to inhibit autophagy and mitophagy, although the underlying molecular mechanisms remain to be determined.

References 

  • 1.
    Swain S.M.; Whaley F.S.; Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer, 2003, 97(11): 2869-2879.
  • 2.
    Singal P.K.; Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med., 1998, 339(13): 900-905.
  • 3.
    Minotti G.; Menna P.; Salvatorelli E.; et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 2004, 56(2): 185-229.
  • 4.
    Yen H.C.; Oberley T.D.; Vichitbandha S.; et al. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J. Clin. Invest., 1996, 98(5): 1253-1260.
  • 5.
    Siveski-Iliskovic N.; Hill M.; Chow D.A.; et al. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation, 1995, 91(1): 10-15.
  • 6.
    Sun X.; Zhou Z.; Kang Y.J. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart. Cancer Res., 2001, 61(8): 3382-3387.
  • 7.
    Gianni L.; Herman E.H.; Lipshultz S.E.; et al. Anthracycline cardiotoxicity: from bench to bedside. J. Clin. Oncol., 2008, 26(22): 3777-3784.
  • 8.
    Ladas E.J.; Jacobson J.S.; Kennedy D.D.; et al. Antioxidants and cancer therapy: a systematic review. J. Clin. Oncol., 2004, 22(3): 517-528.
  • 9.
    Bansal N.; Adams M.J.; Ganatra S.; et al. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardio-Oncology, 2019, 5: 18.
  • 10.
    Injac R.; Strukelj B. Recent advances in protection against doxorubicin-induced toxicity. Technol. Cancer Res. Treat., 2008, 7(6): 497-516.
  • 11.
    Hasinoff B.B.; Herman E.H. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc. Toxicol., 2007, 7(2): 140-144.
  • 12.
    Swain S.M.; Whaley F.S.; Gerber M.C.; et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol., 1997, 15(4): 1318-1332.
  • 13.
    Tebbi C.K.; London W.B.; Friedman D.; et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J. Clin. Oncol., 2007, 25(5): 493-500.
  • 14.
    Seif A.E.; Walker D.M.; Li Y.M.; et al. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatr. Blood Cancer, 2015, 62(4): 704-709.
  • 15.
    Zilinyi R.; Czompa A.; Czegledi A.; et al. The cardioprotective effect of metformin in doxorubicin-induced cardiotoxicity: the role of autophagy. Molecules, 2018, 23(5): 1184.
  • 16.
    Kobashigawa L.C.; Xu Y.C.; Padbury J.F.; et al. Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an in vitro study. PLoS One, 2014, 9(8): e104888.
  • 17.
    Asensio-López M.C.; Lax A.; Pascual-Figal D.A.; et al. Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system. Free Radic. Biol. Med., 2011, 51(10): 1861-1871.
  • 18.
    Ajzashokouhi A.H.; Bostan H.B.; Jomezadeh V.; et al. A review on the cardioprotective mechanisms of metformin against doxorubicin. Hum. Exp. Toxicol., 2020, 39(3): 237-248.
  • 19.
    Singh M.; Nicol A.T.; DelPozzo J.; et al. Demystifying the relationship between metformin, AMPK, and doxorubicin cardiotoxicity. Front. Cardiovasc. Med., 2022, 9: 839644.
  • 20.
    Li Y.; Luo J.; Lin M.T.; et al. Co-delivery of metformin enhances the antimultidrug resistant tumor effect of doxorubicin by improving hypoxic tumor microenvironment. Mol. Pharmaceutics, 2019, 16(7): 2966-2979.
  • 21.
    El-Ashmawy N.E.; Khedr N.F.; El-Bahrawy H.A.; et al. Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway. Tumour Biol., 2017, 39(5): 1010428317692235.
  • 22.
    Rena G.; Hardie D.G.; Pearson E.R. The mechanisms of action of metformin. Diabetologia, 2017, 60(9): 1577-1585.
  • 23.
    Fujita Y.; Inagaki N. Metformin: clinical topics and new mechanisms of action. Diabetol. Int., 2017, 8(1): 4-6.
  • 24.
    Eurich D.T.; McAlister F.A.; Blackburn D.F.; et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ, 2007, 335(7618): 497.
  • 25.
    Johnson J.A.; Majumdar S.R.; Simpson S.H.; et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care, 2002, 25(12): 2244-2248.
  • 26.
    Nesti L.; Natali A. Metformin effects on the heart and the cardiovascular system: a review of experimental and clinical data. Nutr., Metab. Cardiovasc. Dis., 2017, 27(8): 657-669.
  • 27.
    Xu X.; Lu Z.B.; Fassett J.; et al. Metformin protects against systolic overload-induced heart failure independent of AMP-activated protein kinase α2. Hypertension, 2014, 63(4): 723-728.
  • 28.
    Tzanavari T.; Varela A.; Theocharis S.; et al. Metformin protects against infection-induced myocardial dysfunction. Metabolism, 2016, 65(10): 1447-1458.
  • 29.
    Soraya H.; Clanachan A.S.; Rameshrad M.; et al. Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction. Eur. J. Pharmacol., 2014, 737: 77-84.
  • 30.
    Loi H.; Boal F.; Tronchere H.; et al. Metformin protects the heart against hypertrophic and apoptotic remodeling after myocardial infarction. Front. Pharmacol., 2019, 10: 154.
  • 31.
    Driver C.; Bamitale K.D.S.; Kazi A.; et al. Cardioprotective effects of metformin. J. Cardiovasc. Pharmacol., 2018, 72(2): 121-127.
  • 32.
    Apaijai N.; Pintana H.; Chattipakorn S.C.; et al. Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet. Endocrinology, 2012, 153(8): 3878-3885.
  • 33.
    Yu J.M.; Hsieh M.C.; Qin L.; et al. Metformin reduces radiation-induced cardiac toxicity risk in patients having breast cancer. Am. J. Cancer Res., 2019, 9(5): 1017-1026.
  • 34.
    Kheirandish M.; Mahboobi H.; Yazdanparast M.; et al. Anti-cancer effects of metformin: recent evidences for its role in prevention and treatment of cancer. Curr. Drug Metab., 2018, 19(9): 793-797.
  • 35.
    Zi F.M.; Zi H.P.; Li Y.; et al. Metformin and cancer: an existing drug for cancer prevention and therapy. Oncol. Lett., 2018, 15(1): 683-690.
  • 36.
    Berthiaume J.M.; Wallace K.B. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol., 2007, 23(1): 15-25.
  • 37.
    Bianchi C.; Bagnato A.; Paggi M.G.; et al. Effect of adriamycin on electron transport in rat heart, liver, and tumor mitochondria. Exp. Mol. Pathol., 1987, 46(1): 123-135.
  • 38.
    Davies K.J.; Doroshow J.H. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J. Biol. Chem., 1986, 261(7): 3060-3067.
  • 39.
    Doroshow J.H.; Davies K.J. Redox cycling of anthracyclines by cardiac mitochondria. Ⅱ. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J. Biol. Chem., 1986, 261(7): 3068-3074.
  • 40.
    Pereira G.C.; Silva A.M.; Diogo C.V.; et al. Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol. Curr. Pharm. Des., 2011, 17(20): 2113-2129.
  • 41.
    Wallace K.B. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol. Toxicol., 2003, 93(3): 105-115.
  • 42.
    Wallace K.B. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc. Toxicol., 2007, 7(2): 101-107.
  • 43.
    Zhou S.; Starkov A.; Froberg M.K.; et al. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res., 2001, 61(2): 771-777.
  • 44.
    Nah J.; Miyamoto S.; Sadoshima J. Mitophagy as a protective mechanism against myocardial stress. Comprehensive Physiology, 2017, 7(4): 1407-1424.
  • 45.
    Sentelle R.D.; Senkal C.E.; Jiang W.H.; et al. Erratum: ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat. Chem. Biol., 2012, 8(12): 1008.
  • 46.
    Mizumura K.; Cloonan S.M.; Nakahira K.; et al. Mitophagy-dependent necroptosis contributes to the pathogenesis of COPD. J. Clin. Invest., 2014, 124(9): 3987-4003.
  • 47.
    Catanzaro M.P.; Weiner A.; Kaminaris A.; et al. Doxorubicin-induced cardiomyocyte death is mediated by unchecked mitochondrial fission and mitophagy. FASEB J., 2019, 33(10): 11096-11108.
  • 48.
    Teng A.C.T.; Miyake T.; Yokoe S.;et al. Metformin increases degradation of phospholamban via autophagy in cardiomyocytes. Proc. Natl. Acad. Sci. U. S. A., 2015, 112(23): 7165-7170.
  • 49.
    Xie Z.L.; Lau K.; Eby B.; et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes, 2011, 60(6): 1770-1778.
  • 50.
    Wang G.Y.; Bi Y.G.; Liu X.D.; et al. Autophagy was involved in the protective effect of metformin on hyperglycemia-induced cardiomyocyte apoptosis and Connexin43 downregulation in H9c2 cells. Int. J. Med. Sci., 2017, 14(7): 698-704.
  • 51.
    Kanamori H.; Naruse G.; Yoshida A.; et al. Metformin enhances autophagy and provides cardioprotection in δ-sarcoglycan deficiency-induced dilated cardiomyopathy. Circ. Heart Fail., 2019, 12(4): e005418.
  • 52.
    Arinno A.; Maneechote C.; Khuanjing T.; et al. Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics. Biochem. Pharmacol., 2021, 192: 114743.
  • 53.
    Xu X.M.; Kobayashi S.; Chen K.; et al. Diminished autophagy limits cardiac injury in mouse models of type 1 diabetes. J. Biol. Chem., 2013, 288(25): 18077-18092.
  • 54.
    Xu X.M.; Chen K.; Kobayashi S.; et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy. J. Pharmacol. Exp. Ther., 2012, 341(1): 183-195.
  • 55.
    Kobayashi S.; Xu X.M.; Chen K.; et al. Suppression of autophagy is protective in high glucose-induced cardiomyocyte injury. Autophagy, 2012, 8(4): 577-592.
  • 56.
    Kobayashi S.; Patel J.; Zhao F.Y.; et al. Novel dual-fluorescent mitophagy reporter reveals a reduced mitophagy flux in type 1 diabetic mouse heart. J. Am. Osteopath. Assoc., 2020, 120(7): 446-455.
  • 57.
    Kobayashi S.; Lackey T.; Huang Y.; et al. Transcription factor gata4 regulates cardiac BCL2 gene expression in vitro and in vivo. FASEB J., 2006, 20(6): 800-802.
  • 58.
    Kobayashi S.; Volden P.; Timm D.; et al. Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. J. Biol. Chem., 2010, 285(1): 793-804.
  • 59.
    Chen K.; Xu X.M.; Kobayashi S.; et al. Caloric restriction mimetic 2-deoxyglucose antagonizes doxorubicin-induced cardiomyocyte death by multiple mechanisms. J. Biol. Chem., 2011, 286(25): 21993-22006.
  • 60.
    Reni M.; Dugnani E.; Cereda S.; et al. (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized phase Ⅱ trial. Clin. Cancer Res., 2016, 22(5): 1076-1085.
  • 61.
    Zheng Y.; Zhu J.; Zhang H.Y.; et al. Metformin plus first-line chemotherapy versus chemotherapy alone in the treatment of epithelial ovarian cancer: a prospective open-label pilot trial. Cancer Chemother. Pharmacol., 2019, 84(6): 1349-1357.
  • 62.
    Nanni O.; Amadori D.; De Censi A.; et al. Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial. Breast Cancer Res. Treat., 2019, 174(2): 433-442.
  • 63.
    Trucco M.; Barredo J.C.; Goldberg J.; et al. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin. Pediatr. Blood Cancer, 2018, 65(9): e27224.
  • 64.
    Montalvo R.N.; Doerr V.; Kwon O.S.; et al. Protection against doxorubicin-induced cardiac dysfunction is not maintained following prolonged autophagy inhibition. Int. J. Mol. Sci., 2020, 21(21): 8105.
  • 65.
    Ding Y.H.; Sun X.J.; Xu X.L. TOR-autophagy signaling in adult zebrafish models of cardiomyopathy. Autophagy, 2012, 8(1): 142-143.
  • 66.
    Zhu W.Q.; Soonpaa M.H.; Chen H.Y.; et al. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation, 2009, 119(1): 99-106.
  • 67.
    Sishi B.J.N.; Loos B.; Van Rooyen J.; et al. Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity. Biochem. Pharmacol., 2013, 85(1): 124-134.
  • 68.
    Kawaguchi T.; Takemura G.; Kanamori H.; et al. Prior starvation mitigates acute doxorubicin cardiotoxicity through restoration of autophagy in affected cardiomyocytes. Cardiovasc. Res., 2012, 96(3): 456-465.
  • 69.
    Li D.L.; Wang Z.V.; Ding G.Q.; et al. Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification. Circulation, 2016, 133(17): 1668-1687.
  • 70.
    Koleini N.; Kardami E. Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget, 2017, 8(28): 46663-46680.
  • 71.
    Hoshino A.; Mita Y.; Okawa Y.; et al. Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart. Nat. Commun., 2013, 4: 2308.
  • 72.
    Yin J.; Guo J.B.; Zhang Q.; et al. Doxorubicin-induced mitophagy and mitochondrial damage is associated with dysregulation of the PINK1/parkin pathway. Toxicol. In Vitro, 2018, 51: 1-10.
  • 73.
    Katayama H.; Kogure T.; Mizushima N.; et al. A sensitive and quantitative technique for detecting autophagic events based on lysosomal delivery. Chem. Biol., 2011, 18(8): 1042-1052.
  • 74.
    McWilliams T.G.; Prescott A.R.; Allen G.F.G.; et al. mito-QC illuminates mitophagy and mitochondrial architecture in vivo. J. Cell Biol., 2016, 214(3): 333-345.
  • 75.
    Klionsky D.J.; Abdel-Aziz A.K.; Abdelfata S.; et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy, 2021, 17(1): 1-382
Share this article:
Download PDF
DOI
10.53941/ijddp.0201004
Issue
Volume 2, Issue 1
How to Cite
Van, J.; Hahn, Y.; Silverstein, B.; Li, C.; Cai, F.; Wei, J.; Katiki, L.; Mehta, P.; Livatova, K.; DelPozzo, J.; Kobayashi, T.; Huang, Y.; Kobayashi, S.; Liang, Q. Metformin Inhibits Autophagy, Mitophagy and Antagonizes Doxorubicin-Induced Cardiomyocyte Death. International Journal of Drug Discovery and Pharmacology 2023, 2 (1), 37–51. https://doi.org/10.53941/ijddp.0201004.
RIS
BibTex
Copyright & License
article copyright Image
Jennifer Van, Younghee Hahn, Brett Silverstein, Cairong Li, Fei Cai, Jia Wei, Lokesh Katiki, Puja Mehta, Katherine Livatova, Jaclyn DelPozzo, Tamayo Kobayashi, Yuan Huang, Satoru Kobayashi, Qiangrong Liang